tafenoquineTreatment for Malaria Prophylaxis
GSK Submits US Regulatory Application for Single-Dose Tafenoquine for Plasmodium vivax Malaria
London, UK; Geneva, Switzerland - 28 November 2017 -- GSK and Medicines for Malaria Venture (MMV) today announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients 16 years of age and older. If approved, tafenoquine would be the first new medicine for the prevention of relapse of P vivax malaria in more than 60 years, potentially addressing the need for a single-dose and effective medicine for this debilitating disease.
The submission follows the decision made by FDA in December 2013 to grant tafenoquine Breakthrough Therapy Designation, an initiative aimed at expediting the development and review times of drugs for serious or life-threatening conditions. The NDA submission includes Phase III data from the previously reported GATHER and DETECTIVE studies conducted by GSK in partnership with MMV.
Pauline Williams, Head of Global Health R&D, GSK said: “This regulatory filing marks a significant and historical milestone in our global health efforts. Treating Plasmodium vivax malaria is particularly challenging because the parasite can lie dormant in the liver resulting in relapses. Poor compliance to primaquine in real-world settings can lead to higher relapse rates than those seen in the controlled setting of clinical trials, so a single dose treatment is an attractive proposition. GSK and MMV have been working together since 2008 to develop single-dose tafenoquine as an alternative to primaquine. If approved, tafenoquine will potentially become an important tool to help eliminate P vivax malaria for good. We look forward to the outcome of the filing.”
David Reddy, CEO of Medicines for Malaria Venture said, “MMV and GSK are committed to the development of single-dose tafenoquine for relapsing malaria. Following a long-standing partnership, we have now reached the exciting milestone of regulatory filing. This is significant because without treatment to stop the relapses, infected patients live with the constant threat of malarial symptoms returning without warning. Relapsing malaria thereby contributes significantly to the burden of disease in affected countries. The world has been waiting over 60 years for a new medicine for this indication. A single dose medicine would be unprecedented.”
Tafenoquine is not approved for use anywhere in the world. GSK plans to progress regulatory filings in other countries in 2017 and 2018.
About Plasmodium vivax malaria
The Plasmodium parasite is a complex organism with a lifecycle spanning both humans and mosquitoes. After an infected mosquito bite, the P. vivax parasite has the ability to lie dormant in the liver (known as a hypnozoite) and periodically reactivate causing relapses of P. vivax malaria. Hence, a single P. vivax infection can give rise to multiple episodes of malaria, in the absence of a new mosquito bite. These relapses can occur weeks or even years after the initial infection.
P. vivax malaria has a significant public health and economic impact, primarily in South and South East Asia, Latin America and the horn of Africa. The disease is estimated to cause around 8.5 million clinical infections every year. Each of these infections keeps a child or adult from school or work for at least 3 days. Studies have shown that beyond lost time, malaria can also have adverse effects on cognitive ability.,
Tafenoquine was first synthesised by scientists at the Walter Reed Army Institute of Research in 1978. GSK entered into a collaboration with MMV in 2008 to develop tafenoquine as an anti-relapse medicine for patients infected with P. vivax. It is an investigational 8-aminoquinoline derivative with activity against the P. vivax lifecycle, including hypnozoites.
GSK’s commitment to malaria
Malaria is one of the greatest global healthcare challenges of today. Whilst progress has been made in the fight against malaria this progress is fragile. At GSK, we want to help change this and maintain momentum. That’s why we will continue to make our expertise available and continue to collaborate with many different types of organisations across the world in a number of key areas including investing in research to help discover new medicines and vaccines for malaria, making treatments available to as many people who need them as possible, working in collaboration with communities to help build core skills through education helping improve local healthcare services and advocating in support of the global malaria community to ensure that there are sufficient resources to combat malaria.
GSK – a science-led global healthcare company with a special purpose: to help people to do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
Medicines for Malaria Venture (MMV) - MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
Since its foundation in 1999, MMV and partners have built the largest portfolio of antimalarial R&D and access projects ever assembled, and brought forward seven new medicines that are already saving lives. MMV's success is based on its extensive partnership network of over 400 pharmaceutical, academic and endemic-country partners in more than 55 countries.
MMV's vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.
For more information visit www.mmv.org
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.
 World Health Organization. World Malaria Report 2016 (2016): http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/
 Price RN et al. “Vivax malaria: neglected and not benign.” Am J Trop Med Hyg 77:79–87 (2007).
 Vitor-Silva S et al. “Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon.” Malar J. 8:230 (2009).
 Fernando SD et al. “The impact of repeated malaria attacks on the school performance of children.” Am J Trop Med Hyg. 69(6):582-8 (2003).
Posted: November 2017
- 60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria Drug - February 8, 2018
- 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine - December 18, 2017